Literature DB >> 23918685

Increased cardiovascular risk in South African patients with Addison's disease.

I L Ross1, R Bergthorsdottir, N S Levitt, D A Schatz, G Johannsson, A D Marais.   

Abstract

Patients with Addison's disease (AD) are believed to be at risk for cardiovascular disease (CVD). South Africa, like the rest of the developing world is experiencing an increase in CVD and patients with AD may be at double the risk of their peers. We wished to explore AD patients' CVD risk factors. A cross-sectional nationwide study in South Africa of patients with AD was conducted. A cohort of 147 patients with AD and 147 healthy control subjects were matched by age, gender, ethnicity, and BMI as far as was possible. Lipoproteins and highly-sensitive C-reactive-protein (hs-CRP) were the main outcome measures. AD patients had significantly higher triglycerides; (p=0.001), lower HDLC (p<0.001), higher hs-CRP (p<0.001), and more small dense LDL; (p=0.002) than controls. Nonesterified fatty acids were lower in patients (p<0.001). Approximately 65% [95% confidence interval (CI 55.6-72.4%)] had hypercholesterolaemia, 75% (CI 64.8-81.2%) had low HDLC, and 75% (CI 68.0-84.1%) had a higher LDLC. Thirteen percent of AD patients had diabetes mellitus, but none of the risk factors differed from the nondiabetics. Only HDLC correlated positively with daily hydrocortisone dose (r=0.32; p=0.005). In conclusion dyslipidaemia is common in South African AD patients; CVD risk assessment and intervention are probably warranted in the management of these patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23918685     DOI: 10.1055/s-0033-1351259

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.

Authors:  Roberta Giordano; Federica Guaraldi; Elisa Marinazzo; Federica Fumarola; Alessia Rampino; Rita Berardelli; Ioannis Karamouzis; Manuela Lucchiari; Tilde Manetta; Giulio Mengozzi; Emanuela Arvat; Ezio Ghigo
Journal:  Endocrine       Date:  2015-07-17       Impact factor: 3.633

Review 2.  Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review.

Authors:  Laura Maria Mongioì; Rosita Angela Condorelli; Federica Barbagallo; Sandro La Vignera; Aldo Eugenio Calogero
Journal:  Endocrine       Date:  2020-01-11       Impact factor: 3.633

3.  Steroid replacement in primary adrenal failure does not appear to affect circulating adipokines.

Authors:  Marta Fichna; Piotr Fichna; Maria Gryczyńska; Agata Czarnywojtek; Magdalena Żurawek; Marek Ruchała
Journal:  Endocrine       Date:  2014-08-17       Impact factor: 3.633

4.  Cardiovascular risk factors in patients with Addison's disease: a comparative study of South African and Swedish patients.

Authors:  Ian Louis Ross; Ragnhildur Bergthorsdottir; Naomi Levitt; Joel Alex Dave; Desmond Schatz; David Marais; Gudmundur Johannsson
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

5.  Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life.

Authors:  L M Mongioì; R A Condorelli; S La Vignera; A E Calogero
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

6.  Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.

Authors:  V Guarnotta; C Di Stefano; A Santoro; A Ciresi; A Coppola; C Giordano
Journal:  Endocr Connect       Date:  2019-07-01       Impact factor: 3.335

Review 7.  The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids.

Authors:  Henrik Oster; Etienne Challet; Volker Ott; Emanuela Arvat; E Ronald de Kloet; Derk-Jan Dijk; Stafford Lightman; Alexandros Vgontzas; Eve Van Cauter
Journal:  Endocr Rev       Date:  2017-02-01       Impact factor: 19.871

8.  Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia.

Authors:  Daniela Esposito; Emanuele Bobbio; Rosa Di Fraia; Pasquale Mone; Giacomo Accardo; Annamaria De Bellis; Sergio Iorio; Katherine Esposito; Raffaele Marfella; Gudmundur Johannsson; Oskar Ragnarsson; Daniela Pasquali
Journal:  Endocrine       Date:  2020-08-19       Impact factor: 3.633

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.